MENU
+Compare
SABS
Stock ticker: NASDAQ
AS OF
Jun 6 closing price
Price
$1.81
Change
-$0.02 (-1.09%)
Capitalization
17.05M

SABS SAB Biotherapeutics Forecast, Technical & Fundamental Analysis

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum... Show more

SABS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for SABS with price predictions
May 28, 2025

SABS's Stochastic Oscillator sits in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

SABS moved above its 50-day moving average on April 25, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SABS crossed bullishly above the 50-day moving average on April 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SABS advanced for three days, in of 162 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 70 cases where SABS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SABS moved out of overbought territory on May 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on May 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SABS as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SABS turned negative on May 21, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SABS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SABS broke above its upper Bollinger Band on May 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.796) is normal, around the industry mean (16.080). P/E Ratio (0.000) is within average values for comparable stocks, (59.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.197). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (268.270).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SABS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SABS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SABS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

SABS is expected to report earnings to rise 48.80% to -83 cents per share on March 28

SAB Biotherapeutics SABS Stock Earnings Reports
Q4'23
Est.
$-0.83
Q1'25
Missed
by $0.44
Q3'23
Missed
by $0.88
Q2'23
Missed
by $1.26
Q1'23
Missed
by $1.39
The last earnings report on May 09 showed earnings per share of -56 cents, missing the estimate of -11 cents. With 2.93K shares outstanding, the current market capitalization sits at 17.05M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2100 East 54th Street North
Phone
+1 605 679-6980
Employees
57
Web
https://www.sabbiotherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

SABS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SABS has been loosely correlated with LPTX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then LPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
-1.12%
LPTX - SABS
47%
Loosely correlated
+2.36%
SLS - SABS
32%
Poorly correlated
-7.77%
MGX - SABS
32%
Poorly correlated
-0.60%
INKT - SABS
28%
Poorly correlated
-5.49%
VERV - SABS
28%
Poorly correlated
-1.17%
More